Results 211 to 220 of about 115,050 (245)

Identifying a Csmd3+ Microglial Subpopulation that Drives Cold‐to‐Hot Transition and Immune‐Cure in Glioblastoma

Advanced Science, EarlyView.
The study establishes an immune‐cure (ICu) mouse model based on a TMEMed G422TN‐GBM system that faithfully recapitulates human TMEMed GBM. scRNA‐seq analysis reveals a Csmd3+ microglial subset with innate immune memory (IIM) potential that potently suppresses GBM growth, drives a TME cold‐to‐hot transition, and induces 100% ICu in long‐term survival ...
Hai‐Feng Jiang, Pan‐Pan Gao, Yu‐Wen Du, Li‐Qin Wu, En‐Zhi Yin, Qi An, Ze‐Hua Ding, Jin‐Wen Shi, Ya Shu, Ruoqiao Chen, Feng Liu, Mingfeng Li, Xiao Qian Chen   +12 more
wiley   +1 more source

AI‐Assisted Engineering of Glycyrrhizic Acid/Simvastatin Nanocrystals for Multifunctional Treatment of Bacterial Osteomyelitis

Advanced Science, EarlyView.
Through AI‐assisted screening from FDA‐approved API to overcome the limitations of bacterial osteomyelitis treatment, glycyrrhizic acid and simvastatin are identified as a multifunctional combination capable of self‐assembling into mechanism‐targeting nanocrystals that effectively neutralize reactive oxygen species, suppress M1 macrophage polarization,
Yu Han, Yao Zhao, Chengbo Yang, Miao Niu, Jun Dai, Quanxin Ning, Kai Xiao, Jinzheng Liang, Wensheng Zhang, Liang Wang, Dan Shao, Dongsong Li   +11 more
wiley   +1 more source

Chronic HBV Infection Disrupts CCL5‐Secreting cNK Cells and Attenuates Liver Accumulation and Activation of DCs and HBV‐Specific T Cells

Advanced Science, EarlyView.
ADORA2A activation suppresses NFκB‐dependent CCL5 production in cNK cells during chronic HBV infection, disrupting intrahepatic DC recruitment and HBV‐specific CD8+ T‐cell differentiation and function. Targeting the ADORA2A/NFκB/CCL5 axis restores antiviral immunity and facilitates HBV clearance.
Ailu Yang, Yucan Wang, Yating Yu, Jing Wu, Cuiping Bao, Zixuan Wang, Qiuju Han, Zhigang Tian, Jian Zhang, Huajun Zhao   +9 more
wiley   +1 more source

Programmable Encapsulation Enables On‐Demand Proliferation of Therapeutic Bacteria for Potent Cancer Immunotherapy

Advanced Science, EarlyView.
A programmable encapsulation technology is developed to reduce bacterial immunogenicity and proliferation after systemic administration. The cross‐linked polymer networks around individual bacteria enable immunogenic shielding and permit selective proliferation in tumors, allowing the bacteria to convert tumor‐accumulated ammonia into L‐arginine and ...
Jianhui Yang, Ao Peng, Shuaiqiang Li, Yaning Huang, Jian Yan, Leyuan Wang, Zhihui Zhu, Fei‐Long Liu, Erbao Bian, Yang Liu, Dasheng Tian, Fenghe Li, Qi Liu   +12 more
wiley   +1 more source

Immediate Growth Control in Response to Boiling Histotripsy is Prognostic for Intratumoral Immune Activation

Advanced Science, EarlyView.
Boiling Histrotripsy (BH), a mechanical form of focused ultrasound (FUS), allows for non‐invasive and non‐ionizing tissue destruction. Utilizing a BH treatment protocol that yielded bifurcating primary tumor growth responses, we found that immediate BH‐induced tumor growth control identifies tumors with acute reductions in antigen‐presenting cells (APC)
Lydia E. Kitelinger, Matthew R. DeWitt, Carly M. Van Wagoner, Claire A. Conarroe, Charles C. Funk, Aaron B. Streit, AeRyon Kim, Richard J. Price, Timothy N. J. Bullock   +8 more
wiley   +1 more source

Engineering‐Modulated Molybdenum Enzymes Strategy for Tumor‐Specific Metabolic‐Immunotherapy

Advanced Science, EarlyView.
Biodegradable molybdenum sulfide nanoparticles were synthesized via a one‐pot strategy to increase molybdenum enzyme activity and thus effectively potentiate anti‐tumor immunity by integrating molybdenum‐based metalloimmunotherapy with hydrogen sulfide gas therapy.
Xiaoxiao Pan, Zifan Pei, Jie Wu, Nan Jiang, Qian Li, Yuqi Yang, Jie Cao, Yechen Huang, Shumin Sun, Qialu Du, Zhicheng Liu, Lin Zhang, Fei Gong, Jinhua Zhou, Liang Cheng   +14 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cancer Immunotherapy with Cytokine-Induced Killer Cells

Targeted Oncology, 2017
Cytokine-induced killer (CIK) cells form under certain stimulation conditions in cultures of peripheral blood mononuclear cells (PBMCs). They are a heterogeneous immune cell population and contain a high percentage of cells with a mixed T-NK phenotype (CD3+CD56+).
Juan J, Mata-Molanes, Manuel, Sureda González, Belén, Valenzuela Jiménez, Elena Mª, Martínez Navarro, Antonio, Brugarolas Masllorens   +4 more
openaire   +2 more sources

Is there a Role for Cytokine-Induced Killer Cells in Cancer Immunotherapy?

Immunotherapy, 2012
867 ISSN 1750-743X 10.2217/IMT.12.89 © 2012 Future Medicine Ltd Immunotherapy (2012) 4(9), 867–869 “There is no doubt that the use of cytokine-induced killer cells holds promise but only the future will tell us whether this relatively simple form of adoptive cellular immunotherapy will really have an impact on the still dismal prognosis of patients ...
Rutella, Sergio, Locatelli, Franco
openaire   +2 more sources

Promising immunotherapy: Highlighting cytokine‐induced killer cells

Journal of Cellular Biochemistry, 2018
AbstractFor many years, cancer therapy has appeared to be a challenging issue for researchers and physicians. By the introduction of novel methods in immunotherapy, the prospect of cancer therapy even more explained than before. Cytokine‐induced killer (CIK) cell‐based immunotherapy demonstrated to have potentiality in improving clinical outcomes and ...
Solmaz Shirjang, Nazila Alizadeh, Behzad Mansoori, Ata Mahmoodpoor, Hossein Samadi Kafil, Mohammad Hojjat‐Farsangi, Mehdi Yousefi   +6 more
openaire   +2 more sources

Activated T cells and cytokine-induced CD3 + CD56 + killer cells

Annals of Hematology, 1997
Over the past two decades, attempts have been made to develop immunotherapy for patients with cancer. A significant obstacle to the development of successful adoptive immunotherapy has been the availability of appropriate cytotoxic cells. Immunologic effector cells such as lymphokine-activated killer (LAK) cells, activated T cells such as tumor ...
Schmidt-Wolf I G H, I G Schmidt-Wolf, R S Negrin   +2 more
exaly   +3 more sources